Long-acting delivery systems for peptides: Inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules

T. W. Redding, A. V. Schally, T. R. Tice, W. E. Meyers

Research output: Contribution to journalArticle

130 Scopus citations

Abstract

Intramuscular injection of [6-D-tryptophan]-luteinizing hormone-releasing hormone ([D-Trp6]LH-RH) in microcapsules of poly(DL-lactide-co-glycolide), designed to release a controlled dose of the peptide over a 30-day period, decreased the weights of androgen-dependent Dunning prostate tumors in rats and suppressed serum testosterone levels more effectively than daily subcutaneous administration of equivalent or double doses of unencapsulated [D-Trp6]LH-RH. The microcapsules or daily injections of [D-Trp6]LH-RH also significantly decreased tumor volumes. Microcapsules of [D-Trp6]LH-RH or related analogs that can be injected once a month should make the treatment of patients with prostate carcinoma and other neoplasms or disorders more convenient and efficacious.

Original languageEnglish (US)
Pages (from-to)5845-5848
Number of pages4
JournalProceedings of the National Academy of Sciences of the United States of America
Volume81
Issue number18 I
DOIs
StatePublished - 1984

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Long-acting delivery systems for peptides: Inhibition of rat prostate tumors by controlled release of [D-Trp<sup>6</sup>]luteinizing hormone-releasing hormone from injectable microcapsules'. Together they form a unique fingerprint.

  • Cite this